Announcements Trials
Browse Landscape

Phase

Phase 1 27Phase 2 16Phase 1/2 8Phase NA 7Phase 3 2Phase EARLY_PHASE1 1

Status

Completed 3Withdrawn 2Terminated 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 15Glioblastoma 14Neoplasms 12Melanoma 11Brain Neoplasms 11Head and Neck Neoplasms 10Carcinoma, Non-Small-Cell Lung 10Pancreatic Neoplasms 9Lung Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Prostatic Neoplasms 8Glioma 8Ovarian Neoplasms 7Neoplasm Metastasis 7Lymphoma 6Colonic Neoplasms 6Multiple Myeloma 5Carcinoma, Hepatocellular 5Urinary Bladder Neoplasms 4Sarcoma 4Rectal Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, T-Cell 4Lymphoma, Large B-Cell, Diffuse 4Hodgkin Disease 4Stomach Neoplasms 3Recurrence 3Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Leukemia, Myeloid, Acute 3

Interventions

bemcentinib 1Postoperative Period 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Terminated × Central Nervous System Neoplasms × Clear all
NCT03965494 2024-02-08

AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase EARLY_PHASE1 Terminated
10 enrolled
CNS

Glioblastoma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡